Peter LeWitt

Peter LeWitt

UNVERIFIED PROFILE

Are you Peter LeWitt?   Register this Author

Register author
Peter LeWitt

Peter LeWitt

Publications by authors named "Peter LeWitt"

Are you Peter LeWitt?   Register this Author

99Publications

1429Reads

17Profile Views

Focused ultrasound opening of the blood-brain barrier for treatment of Parkinson's disease.

Mov Disord 2019 Sep 28;34(9):1274-1278. Epub 2019 May 28.

Department of Neurological Sciences, Rush University School of Medicine, Chicago, Illinois, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27722DOI Listing
September 2019

Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill) in Parkinson's disease.

Parkinsonism Relat Disord 2019 Aug 22;65:131-138. Epub 2019 May 22.

Intec Pharma, Ltd, Hartom 12, POB 45219, Jerusalem, 91450, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2019.05.032DOI Listing
August 2019

Nighttime Sleep and Daytime Sleepiness Improved With Pimavanserin During Treatment of Parkinson's Disease Psychosis.

Clin Neuropharmacol 2018 Nov/Dec;41(6):210-215

Departments of Psychiatry and Medicine, University of California, San Diego, La Jolla, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WNF.0000000000000307DOI Listing
December 2018

Pimavanserin use in a movement disorders clinic: a single-center experience.

Neurol Sci 2018 Oct 21;39(10):1767-1771. Epub 2018 Jul 21.

Parkinson's Disease and Movement Disorders Center, Department of Neurology, Henry Ford Hospital West Bloomfield, 2799 W Grand Blvd., K-11, Detroit, MI, 48202, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10072-018-3500-5DOI Listing
October 2018

At last, a randomised controlled trial of apomorphine infusion.

Authors:
Peter A LeWitt

Lancet Neurol 2018 09 25;17(9):732-733. Epub 2018 Jul 25.

Departments of Neurology, Henry Ford Hospital, West Bloomfield, MI 48322, USA; Wayne State University School of Medicine, Detroit, MI, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(18)30284-9DOI Listing
September 2018

Cervical Dystonia and Executive Function: A Pilot Magnetoencephalography Study.

Brain Sci 2018 Aug 22;8(9). Epub 2018 Aug 22.

Department of Neurology, Henry Ford Hospital, 2799 W. Grand Boulevard, K-11 Detroit, MI 48202, USA.

View Article

Download full-text PDF

Source
http://www.mdpi.com/2076-3425/8/9/159
Publisher Site
http://dx.doi.org/10.3390/brainsci8090159DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162734PMC
August 2018

Comment on 'Distinct Metabolomic Signature in Cerebrospinal Fluid in Early Parkinson's Disease' by Hiller et al.

Authors:
Peter A LeWitt

Mov Disord 2018 05 3;33(5):855. Epub 2018 May 3.

Departments of Neurology, Henry Ford Hospital.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27379DOI Listing
May 2018

Delayed Hypersensitivity Reaction to OnabotulinumtoxinA.

Authors:
Peter A LeWitt

Mov Disord Clin Pract 2018 May-Jun;5(3):321-322. Epub 2018 Mar 9.

Department of Neurology Henry Ford Hospital West Bloomfield MI USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mdc3.12575DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174445PMC
March 2018

Post-traumatic Origin of Unilateral Restless Leg Syndrome.

Authors:
Peter A LeWitt

Mov Disord Clin Pract 2018 May-Jun;5(3):323-324. Epub 2018 Mar 23.

Department of Neurology Henry Ford West Bloomfield Hospital West Bloomfield Michigan USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mdc3.12594DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336284PMC
March 2018

Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting.

Neurology 2018 01 13;90(2):74-82. Epub 2017 Dec 13.

From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000004798DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772155PMC
January 2018

Portrayal of progressive supranuclear palsy in the 16th century.

Authors:
Peter LeWitt

Lancet Neurol 2017 12 14;16(12):956-957. Epub 2017 Nov 14.

Department of Neurology, Henry Ford Hospital, West Bloomfield, Detroit, MI, USA; Department of Neurology, Wayne State University School of Medicine, West Bloomfield, Detroit, MI, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(17)30366-6DOI Listing
December 2017

Comparison of the Fahn-Tolosa-Marin Clinical Rating Scale and the Essential Tremor Rating Assessment Scale.

Mov Disord Clin Pract 2018 Jan-Feb;5(1):60-65. Epub 2017 Nov 23.

Department of Neurology Southern Illinois University School of Medicine Springfield IL.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/mdc3.12560
Publisher Site
http://dx.doi.org/10.1002/mdc3.12560DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174461PMC
November 2017

Multimodal Imaging in a Patient with Hemidystonia Responsive to GPi Deep Brain Stimulation.

Case Rep Neurol Med 2017 4;2017:9653520. Epub 2017 Jul 4.

Image Analysis Laboratory, Departments of Radiology and Research Administration, Henry Ford Health System, Detroit, MI 48202, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/9653520DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514339PMC
July 2017

Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry.

J Neurol Sci 2017 May 21;376:84-90. Epub 2017 Feb 21.

Department of Neurological Sciences, Rush University Medical Center, 1725 West Harrison Street, Chicago, IL 60612, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2017.02.042DOI Listing
May 2017

Prospective evaluation of pulmonary function in Parkinson's disease patients with motor fluctuations.

Int J Neurosci 2017 Mar 27;127(3):276-284. Epub 2016 Jun 27.

e Acorda Therapeutics , Chelsea , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/00207454.2016.1194274DOI Listing
March 2017

Metabolomic biomarkers as strong correlates of Parkinson disease progression.

Neurology 2017 Feb 8;88(9):862-869. Epub 2017 Feb 8.

From the Departments of Neurology (P.A.L.) and Public Health Science (J.L., M.L.), Henry Ford Health System; Wayne State University School of Medicine (P.A.L.), Detroit MI; Metabolon, Inc (L.G.), Durham, NC; and Center for Human Experimental Therapeutics (P.A.), University of Rochester, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000003663DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331866PMC
February 2017

The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis.

Clin Neuropharmacol 2016 Mar-Apr;39(2):88-93

*Department of Neurology, Henry Ford Hospital; and †Department of Neurology, Wayne State University School of Medicine, Detroit, MI; ‡Medical University of Innsbruck, Innsbruck, Austria; §Gardner-McMaster Parkinson Center, University of Toledo, Toledo, OH; ∥UCB Pharma, Raleigh, NC; and ¶UCB Pharma, Monheim am Rhein, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WNF.0000000000000133DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791317PMC
December 2016

Nocardia asteroides-Induced movement abnormalities in mice: Relevance for Parkinson's disease?

Mov Disord 2016 08 14;31(8):1134-8. Epub 2016 Jul 14.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.26711DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4981531PMC
August 2016

Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets.

Lancet Neurol 2016 Aug;15(9):954-966

Movement Disorders Clinic and the Edmond J Safra Program in Parkinson's Disease, University Health Network, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(16)30079-5DOI Listing
August 2016

Age-Related Decrease in Heat Shock 70-kDa Protein 8 in Cerebrospinal Fluid Is Associated with Increased Oxidative Stress.

Front Aging Neurosci 2016 26;8:178. Epub 2016 Jul 26.

Department of Neurology, Henry Ford West Bloomfield Hospital, West Bloomfield TownshipMI, USA; Department of Neurology, Wayne State University School of Medicine, DetroitMI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fnagi.2016.00178DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960228PMC
August 2016

Quantitative Analysis of Voice in Parkinson Disease Compared to Motor Performance: A Pilot Study.

J Parkinsons Dis 2015 ;5(3):517-24

Department of Otolaryngology, Henry Ford Health System, Detroit, MI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JPD-140526DOI Listing
July 2016

Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses.

Clin Neuropharmacol 2015 May-Jun;38(3):89-103

*Chulalongkorn Center of Excellence on Parkinson's Disease and Related Disorders, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand; †Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA; ‡National Parkinson Foundation Centre of Excellence, King's College Hospital, Denmark Hill Campus, London, United Kingdom; §Wayne State University School of Medicine, Parkinson's Disease and Movement Disorders Program, Henry Ford West Bloomfield Hospital, West Bloomfield, MI; ║King's College Hospital, Denmark Hill Campus, London, United Kingdom; ¶Chulalongkorn Center of Excellence on Parkinson's Disease and Related Disorders, Bangkok, Thailand; and #Department of Neurology, Movement Disorder Center, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WNF.0000000000000082DOI Listing
April 2016

Levodopa therapy for Parkinson disease: A look backward and forward.

Neurology 2016 Apr 4;86(14 Suppl 1):S3-12. Epub 2016 Apr 4.

From the Department of Neurology (P.A.L.), Henry Ford Hospital; Department of Neurology (P.A.L.), Wayne State University School of Medicine, Detroit, MI; and Department of Neurology (S.F.), Columbia University Medical Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000002509DOI Listing
April 2016

CSF Nrf2 and HSPA8 in Parkinson's disease patients with and without LRRK2 gene mutations.

J Neural Transm (Vienna) 2016 Mar 3;123(3):179-87. Epub 2015 Nov 3.

Department of Neurology, Henry Ford West Bloomfield Hospital, West Bloomfield, MI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00702-015-1479-0DOI Listing
March 2016

New levodopa therapeutic strategies.

Authors:
Peter A LeWitt

Parkinsonism Relat Disord 2016 Jan 8;22 Suppl 1:S37-40. Epub 2015 Sep 8.

Department of Neurology, Henry Ford Hospital and Wayne State University School of Medicine, 6777 West Maple Road, West Bloomfield, MI 48322, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2015.09.021DOI Listing
January 2016

The pharmacodynamics of placebo: expectation effects of price as a proxy for efficacy.

Neurology 2015 Feb 28;84(8):766-7. Epub 2015 Jan 28.

From the Department of Neurology (P.A.L.), Parkinson's Disease and Movement Disorders Center, Henry Ford West Bloomfield Hospital; Department of Neurology (P.A.L.), Wayne State University School of Medicine, Detroit, MI; and Department of Bioethics (S.K.), National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000001294DOI Listing
February 2015

Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics.

Authors:
Peter A LeWitt

Mov Disord 2015 Jan 1;30(1):64-72. Epub 2014 Dec 1.

Parkinson's Disease and Movement Disorders Center, Henry Ford Hospital, West Bloomfield, Michigan, and the Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.26082DOI Listing
January 2015

Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement.

Mov Disord 2014 Dec 9;29(14):1710-9. Epub 2014 Oct 9.

Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.26048DOI Listing
December 2014

SCA 17 phenotype with intermediate triplet repeat number.

J Neurol Sci 2014 Oct 26;345(1-2):269-70. Epub 2014 Jul 26.

Parkinson's Disease and Movement Disorders Program, Henry Ford Hospital, 6777 West Maple Road, West Bloomfield, MI, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2014.07.041DOI Listing
October 2014

Tardive dyskinesia caused by tetrabenazine.

Authors:
Peter A LeWitt

Clin Neuropharmacol 2013 May-Jun;36(3):92-3

Departments of Neurology, Henry Ford Hospital and Wayne State University School of Medicine, Detroit, MI 48322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WNF.0b013e318290cd41DOI Listing
August 2014

Clinician versus machine: reliability and responsiveness of motor endpoints in Parkinson's disease.

Parkinsonism Relat Disord 2014 Jun 5;20(6):590-5. Epub 2014 Mar 5.

Great Lakes NeuroTechnologies Inc., 10055 Sweet Valley Drive, Cleveland, OH 44125, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2014.02.022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4028404PMC
June 2014

Predicting the development of levodopa-induced dyskinesias: a presynaptic mechanism?

Neurology 2014 May 9;82(18):1574-5. Epub 2014 Apr 9.

From the Department of Neurology (P.A.L.), Henry Ford Hospital, Bloomfield; the Department of Neurology (P.A.L.), Wayne State University School of Medicine, Detroit, MI; and Center for Neurodegenerative and Neuroimmunologic Diseases (M.M.M.), Department of Neurology, Rutgers-Robert Wood Johnson Medical School, Piscataway, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000000390DOI Listing
May 2014

Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease.

Mov Disord 2014 Jan 13;29(1):75-82. Epub 2013 Dec 13.

Department of Neurology, Henry Ford Hospital, West Bloomfield, Michigan, USA; Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25742DOI Listing
January 2014

3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis.

Mov Disord 2013 Oct 19;28(12):1653-60. Epub 2013 Jul 19.

Department of Neurology, Henry Ford Hospital, West Bloomfield, Michigan, USA; School of Medicine, Wayne State University, Detroit, Michigan, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25555DOI Listing
October 2013

Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm.

J Neural Transm (Vienna) 2013 Sep 23;120(9):1345-53. Epub 2013 Feb 23.

Parkinson's and Movement Disorder Institute, 9940 Talbert Avenue, Fountain Valley, California, 92708, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00702-013-0998-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751217PMC
September 2013

Actively transported levodopa prodrug XP21279: a study in patients with Parkinson disease who experience motor fluctuations.

Clin Neuropharmacol 2012 May-Jun;35(3):103-10

Department of Neurology, Henry Ford Hospital, West Bloomfield, MI 48322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WNF.0b013e31824e4d7dDOI Listing
March 2013

Treatment of patients with early and advanced Parkinson's disease with rotigotine transdermal system: age-relationship to safety and tolerability.

Parkinsonism Relat Disord 2013 Jan 3;19(1):37-42. Epub 2012 Sep 3.

Department of Neurology, Philipps-Universität, Baldingerstrasse, D 35043 Marburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2012.06.009DOI Listing
January 2013

Abnormal apocrine secretory cell mitochondria in a Huntington disease patient.

J Neurol Sci 2012 Dec 15;323(1-2):261-3. Epub 2012 Sep 15.

Department of Neurology, Henry Ford Hospital, Wayne State University School of Medicine, Detroit, MI 48322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2012.08.034DOI Listing
December 2012

Comparison of dysphagia before and after deep brain stimulation in Parkinson's disease.

Mov Disord 2012 Dec 31;27(14):1763-8. Epub 2012 Oct 31.

Division of Speech-Language Sciences and Disorders, Department of Neurology, Henry Ford Health System, Detroit, Michigan 48322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25259DOI Listing
December 2012

Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study).

Neurology 2012 Jul 27;79(2):163-9. Epub 2012 Jun 27.

Departments of Neurology, Henry Ford Hospital, Detroit, MI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0b013e31825f0451DOI Listing
July 2012

Recent advances in CSF biomarkers for Parkinson's disease.

Authors:
Peter LeWitt

Parkinsonism Relat Disord 2012 Jan;18 Suppl 1:S49-51

Department of Neurology, Henry Ford Hospital, Michigan 48322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1353-8020(11)70017-7DOI Listing
January 2012

Norepinephrine: the next therapeutics frontier for Parkinson's disease.

Authors:
Peter A Lewitt

Transl Neurodegener 2012 Jan 13;1(1). Epub 2012 Jan 13.

Department of Neurology, Henry Ford Hospital and Wayne State University School of Medicine, Detroit, Michigan USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/2047-9158-1-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506997PMC
January 2012

Is levodopa toxic? Insights from a brain bank.

Neurology 2011 Oct 14;77(15):1414-5. Epub 2011 Sep 14.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0b013e31823435a4DOI Listing
October 2011

CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease.

Brain Res 2011 Aug 1;1408:88-97. Epub 2011 Jul 1.

Department of Neurology, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brainres.2011.06.057DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4120020PMC
August 2011

Relief of parkinsonism and dyskinesia: one and the same dopaminergic mechanism?

Authors:
Peter A Lewitt

Neurology 2010 Apr 17;74(15):1169-70. Epub 2010 Mar 17.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0b013e3181d90076DOI Listing
April 2010

Mao-B inhibitor know-how: back to the pharm.

Neurology 2009 Dec;73(23):2048; author reply 2048

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0b013e3181c7756bDOI Listing
December 2009

Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating "off" episodes in advanced Parkinson disease.

Clin Neuropharmacol 2009 Mar-Apr;32(2):89-93

Department of Neurology, Wayne State University School of Medicine and Henry Ford Hospital, Detroit, MI 48034, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WNF.0B013E31816D91F9DOI Listing
September 2009

Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies.

Mov Disord 2009 Jul;24(9):1319-24

Department of Neurology, Henry Ford Hospital and Wayne State University School of Medicine, Detroit, Michigan, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.22587DOI Listing
July 2009

Cellular immune response to intrastriatally implanted allogeneic bone marrow stromal cells in a rat model of Parkinson's disease.

J Neuroinflammation 2009 Jun 5;6:17. Epub 2009 Jun 5.

Division of Neurology, William Beaumont Hospital Research Institute, Royal Oak, Michigan 48073, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1742-2094-6-17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2700085PMC
June 2009

MAO-B inhibitor know-how: back to the pharm.

Authors:
Peter A Lewitt

Neurology 2009 Apr;72(15):1352-7

Department of Neurology, Henry Ford Hospital, Detroit, MI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0b013e3181a0febaDOI Listing
April 2009

Levodopa therapeutics for Parkinson's disease: new developments.

Authors:
Peter A LeWitt

Parkinsonism Relat Disord 2009 Jan;15 Suppl 1:S31-4

Department of Neurology, Henry Ford Hospital, and the Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan 48034, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1353-8020(09)70009-4DOI Listing
January 2009

Levodopa for the treatment of Parkinson's disease.

Authors:
Peter A Lewitt

N Engl J Med 2008 Dec;359(23):2468-76

Department of Neurology, Henry Ford Hospital, and the Department of Neurology, Wayne State University School of Medicine, Detroit, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMct0800326DOI Listing
December 2008

Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure.

Clin Neuropharmacol 2008 Mar-Apr;31(2):63-73

Department of Neuroscience, Neurology, Uppsala University Hospital, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WNF.0b013e3180ed449fDOI Listing
May 2008

Protection against Parkinson's disease progression: clinical experience.

Neurotherapeutics 2008 Apr;5(2):210-25

Department of Neurology, Henry Ford Hospital, Detroit, Michigan, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nurt.2008.01.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084164PMC
April 2008

Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease.

Clin Neuropharmacol 2007 Sep-Oct;30(5):256-65

Department of Neurology, Wayne State University School of Medicine, and Henry Ford Hospital-Franklin Pointe Medical Center, 26400 West 12 Mile Road, Southfield, MI 48034, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/wnf.0b013e318154c7c4DOI Listing
January 2008

A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition.

Authors:
Peter A LeWitt

Clin Neuropharmacol 2007 Sep-Oct;30(5):305-7

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WNF.0b013e318155a7edDOI Listing
January 2008

Apomorphine therapy in Parkinson's disease: a review.

Expert Opin Pharmacother 2007 Nov;8(16):2799-809

Movement Disorders Program, University of Florida, Department of Neurology/McKnight Brain Institute, 100 S. Newell Drive, PO Box 100236, Gainesville, Florida 32610-0236, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.8.16.2799DOI Listing
November 2007

Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study.

Neurology 2007 Apr;68(16):1262-7

Clinical Neuroscience Center, Southfield, MI 48034, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/01.wnl.0000259516.61938.bbDOI Listing
April 2007

TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial.

Lancet Neurol 2006 Dec;5(12):1013-20

Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(06)70602-0DOI Listing
December 2006

Lack of evidence for Nocardia asteroides in brain specimens from Lewy body-containing disorders.

Microb Pathog 2005 Nov-Dec;39(5-6):205-11. Epub 2005 Oct 28.

Department of Neurology, William Beaumont Hospital Research Institute, 3601 West Thirteen Mile Road, Royal Oak, MI 48073, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.micpath.2005.08.001DOI Listing
February 2006

Rotigotine: a viewpoint by Peter LeWitt.

Authors:
Peter LeWitt

CNS Drugs 2005 ;19(11):983-4

Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan and the Clinical Neuroscience Center, Southfield, MI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/00023210-200519110-00008DOI Listing
January 2006

Clinical trials of neuroprotection for Parkinson's disease.

Authors:
Peter A LeWitt

Neurology 2004 Oct;63(7 Suppl 2):S23-31

Departments of Neurology, Psychiatry and Behavioral Neuroscience, Wayne State University School of Medicine, The William Beaumont Hospital Research Institute, Royal Oak, Michigan, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/wnl.63.7_suppl_2.s23DOI Listing
October 2004

Early complement activation increases in the brain in some aged normal subjects.

Neurobiol Aging 2004 Sep;25(8):1001-7

Division of Neurology, William Beaumont Hospital Research Institute, Royal Oak, MI 48073, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurobiolaging.2003.11.003DOI Listing
September 2004

Characterization of dopamine-depleting activity of Nocardia asteroides strain GUH-2 culture filtrate on PC12 cells.

Microb Pathog 2004 Aug;37(2):73-85

Department of Neurology, William Beaumont Hospital Research Institute, 3811 West Thirteen Mile Road, Royal Oak, MI 48073, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S088240100400059
Publisher Site
http://dx.doi.org/10.1016/j.micpath.2004.05.001DOI Listing
August 2004

Subcutaneously administered apomorphine: pharmacokinetics and metabolism.

Authors:
Peter A LeWitt

Neurology 2004 Mar;62(6 Suppl 4):S8-11

Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan, USA.

View Article

Download full-text PDF

Source
http://www.neurology.org/cgi/doi/10.1212/WNL.62.6_suppl_4.S8
Publisher Site
http://dx.doi.org/10.1212/wnl.62.6_suppl_4.s8DOI Listing
March 2004

New developments in levodopa therapy.

Neurology 2004 Jan;62(1 Suppl 1):S9-16

Department of Neurology, Psychiatry and Behavioral Neuroscience, Wayne State University School of Medicine, Detroit, Michigan, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/wnl.62.1_suppl_1.s9DOI Listing
January 2004

Standardized training tools for the UPDRS activities of daily living scale: newly available teaching program.

Mov Disord 2003 Dec;18(12):1455-8

Department of Neurological Sciences, Rush University, Rush-Presbyterian-St Luke's Medical Center, Chicago, Illinois, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.10591DOI Listing
December 2003

Nocardia asteroides culture filtrates cause dopamine depletion and cytotoxicity in PC12 cells.

Neurochem Res 2003 Sep;28(9):1359-67

Division of Neurology, William Beaumont Hospital Research Institute, Royal Oak, Michigan 48073, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1023/a:1024944431725DOI Listing
September 2003